Powered by

-RedHill Biopharma Enters $ 115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners

Feb 26, 2020 - ENP Newswire
Mergers and Acquisitions-Partnership Announcement

TEL-AVIV - RedHill Biopharma Ltd. (Nasdaq: RDHL) ('RedHill' or the 'Company'), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today announced that it has entered into a non-dilutive, royalty-backed term loan agreement with HealthCare Royalty Partners ('HCR') pursuant to which HCR has committed up to $ 115 million to support RedHill's U.S. commercial operations.